Clovis oncology, inc. (CLVS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating activities
Net loss

-99,332

-99,501

-94,073

-120,429

-86,421

-99,259

-89,865

-101,191

-77,694

-51,883

-60,665

-175,385

-58,464

-70,728

-65,695

-129,314

-83,400

-119,541

-98,645

-71,531

-63,144

-54,907

-39,642

-34,764

-30,718

-29,203

-20,320

-19,341

-15,668

-21,059

-18,268

-15,657

-18,999

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense

12,961

12,556

13,979

14,129

13,640

11,375

10,947

14,855

11,913

12,506

12,638

10,616

8,947

10,052

9,202

9,577

10,965

10,899

12,406

8,370

8,682

5,932

5,436

5,213

4,936

2,842

2,791

2,108

1,764

1,341

1,494

1,168

946

Depreciation and amortization

2,130

2,041

2,095

1,910

1,722

2,104

990

921

586

593

630

642

639

322

269

280

270

213

197

182

169

-3,256

143

80

3,477

65

62

61

62

84

93

92

84

Amortization of premiums and discounts on available-for-sale securities

140

252

385

755

129

-266

-386

-864

171

-348

239

-31

-214

-21

-39

-71

-80

-81

-344

-504

-471

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

786

788

746

679

645

642

641

569

326

323

321

318

317

314

312

309

307

305

302

300

298

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of debt issuance costs related to convertible senior notes conversion

3,555

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on convertible senior notes conversion

-7,791

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

65

-1

-169

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent purchase consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-25,710

1,049

-27,760

846

1,916

-2,794

-2,992

-1,727

542

876

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-101

-815

-1,137

-1,206

-60

1,549

-113

-29,062

-4,145

-

-

-

-

0

0

0

761

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on available for sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

Changes in operating assets and liabilities:
Accounts receivable

4,519

3,566

1,461

-714

3,205

-1,607

2,192

-632

3,418

6,182

-1,144

-1,234

2,257

121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-6,839

2,687

-12,167

11,704

23,936

24,396

-10,003

-6,173

41,716

22,163

-1,133

-26

6,504

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and accrued research and development expenses

5,559

-9,940

-8,252

-1,604

-3,437

-7,755

-1,288

535

-637

1,013

1,122

5,115

10,047

487

2,105

5,171

7,601

6,924

-11,017

-2,253

-7,776

-10,960

-2,129

708

-5,731

-1,286

-2,155

-1,101

1,266

90

-1,161

-658

-1,264

Deposit on inventory

12,373

-

-

-

-

-11,823

-9,303

44,633

-11,157

-11,357

31,818

-18,237

18,237

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other operating assets and liabilities

-5,198

1,574

298

64

4,901

1,243

3,626

1,991

1,890

2,320

-32,699

38,078

-1,223

1,319

-1,098

-1,390

130

880

742

1,953

805

-3,031

2,414

1,064

463

990

126

75

-196

590

-42

-210

-321

Accounts payable

4,016

9,905

3,777

-6,782

5,389

1,005

3,905

2,590

-1,730

587

1,848

-10,578

13,780

-1,222

-3,930

926

2,682

1,981

3,786

-1,890

4,228

520

198

137

-2,224

2,421

-708

-2,256

1,501

175

722

-1,075

-580

Other accrued expenses

-3,847

11,427

4,593

1,994

-4,692

5,594

-14,206

11,436

1,466

4,607

-1,217

13,156

-9,990

6,944

653

4,254

-3,984

4,686

-728

4,623

-3,286

2,990

1,583

1,219

-1,910

-1,283

555

598

-1,072

345

450

711

-1,599

Net cash used in operating activities

-82,494

-70,147

-56,980

-98,037

-98,451

-82,727

-72,426

-110,209

-100,635

-65,578

-45,785

-69,102

-80,439

-54,675

-60,335

-67,932

-83,738

-75,689

-71,746

-57,226

-48,405

-33,950

-34,222

-29,345

-19,534

-23,834

-15,591

-17,804

-14,483

-18,633

-14,305

-13,893

-18,553

Investing activities
Purchases of property and equipment

34

403

1,403

253

1,231

1,479

5,555

1,991

217

71

167

196

53

5

5

152

604

1,860

169

190

816

95

282

1,689

220

41

14

19

47

20

130

207

701

Deposits for sale of property and equipment

-

-

-

-

-

-

-

-

-

0

0

0

2,515

65

-65

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale securities

9,962

124,731

129,325

67,364

138,415

-

-

-

-

83,500

0

47,000

133,000

0

0

0

0

0

250,324

0

142,216

-

-

-

-

-

-

-

-

-

-

-

-

Sales of available-for-sale securities

79,803

141,901

183,252

143,345

153,500

195,000

95,000

0

10,000

0

163,500

0

50,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75,000

75,000

25,000

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,000

Acquired in-process research and development - milestone payment

-

0

0

750

15,000

-

-

-

-

0

0

0

1,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

69,807

16,767

52,799

74,978

-1,146

13,521

-105,555

-181,991

9,783

-83,571

163,333

-47,196

-86,668

24,995

75,060

74,848

24,396

-1,859

-109,497

-190

-143,032

-95

-282

-1,689

-220

-9,954

-14

-19

-47

-20

-130

-207

1,299

Financing activities
Proceeds from the sale of common stock, net of issuance costs

163,901

-

-

-

-

-

-

-

-

0

-332

324,946

221,224

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19

Payment of convertible senior notes

164,443

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from borrowings under financing agreement

15,592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options and employee stock purchases

2

740

44

1,389

1,093

770

604

2,079

514

1,818

2,149

6,596

5,674

2,574

659

1,238

705

944

1,954

1,880

1,193

400

0

706

57

368

35

1,282

86

273

0

32

10

Payments on finance leases

357

-

-

-

250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on other long-term liabilities

51

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

14,644

13,206

97,338

8,251

1,093

490

592

386,868

514

1,818

1,817

331,542

226,898

2,574

659

1,238

705

944

300,463

1,880

1,193

378

278,335

706

57

368

-40

260,428

86

273

0

70,027

-9

Effect of exchange rate changes on cash and cash equivalents

-481

526

-283

107

-64

-261

-79

-461

254

57

321

493

72

-432

-39

-148

254

-83

-38

255

-891

-241

-478

-94

123

24

29

1

-19

-2

11

-7

10

Increase (decrease) in cash and cash equivalents

1,476

-39,648

92,874

-14,701

-98,568

-68,977

-177,468

94,207

-90,084

-147,274

119,686

215,737

59,863

-27,538

15,345

8,006

-58,383

-76,687

119,182

-55,281

-191,135

-33,908

243,353

-30,422

-19,574

-33,396

-15,616

242,606

-14,463

-18,382

-14,424

55,920

-17,253

Supplemental disclosure of cash flow information:
Cash paid for interest

4,131

1,875

3,171

1,875

3,594

0

5,594

0

3,594

0

3,594

0

3,594

0

3,594

0

3,594

0

3,593

0

3,714

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Vesting of restricted stock units

5,461

707

452

1,006

3,277

678

1,773

1,948

6,409

2,721

6,822

93

2,534

18

123

34

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets recorded for which payment (has)/has not yet occurred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-975

291